A paper from the Journal of EuroIntervention，it demonstrated that Pulmonary Artery Denervation(PADN) can completely abolish experimental pulmonary arterial hypertension in vivo.

A Paper from JACC: By Mapping the Precise Distribution of Sympathetic Nerves and Optimizing Ablation Points, Pulmonary Artery Denervation (PADN) Effectively Leads to Significant Hemodynamic and Reduces Pulmonary Arterial Pressure.

PADN improves hemodynamics and relieves RV dysfunction in dogs with PAH, which can be associated with the downregulating RAAS activity in local tissue.

PADN is associated with significant improvements in hemodynamics and pulmonary artery remodeling for HF-PH.

First-in-man PADN-1 study : comparing with the control group, the patients who underwent the PADN procedure showed significant reduction of mean PAP, and significant improvement in 6MWD and Tei index.  

Report the effect of PADN on functional capacity and hemodynamics in patients with IPAH not responding optimally to medical therapy.

PADN treatment is associated with significant improvement of 6MWD and less PAH-related event.

Confirm that PADN is associated with significant improvements in hemodynamic and clinical outcomes in patients with CpcPH.

PADN results in significant improvements in survival at a medium of 4.8 years follow-up, especially in patients with PAH in FC 3-4.

PADN improved exercise capacity and clinical outcomes during 6-month follow-up for WHO Group I PAH patients.

PADN improved exercise capacity and clinical outcomes during 6-month follow-up for WHO Group I PAH patients.